AMG 714 20060349 Multiple Dose Study in Moderate to Severe Psoriasis Subjects
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
Investigational drug AMG 714 will be given to 66 subjects with moderate to severe psoriasis
to study safety, pharmacokinetics, and efficacy. Dose levels include 150mg and 300mg and will
be given to each subject for a total of 6 doses. Each dose for each subject will be given
once every 2 weeks. Subjects will followed for up to 300 days post the first dose of AMG 714.